Pyrazinamide (PZA) is a unique frontline drug for shortening tuberculosis (TB) treatment, but its mechanisms of action are elusive. We previously found one PZA-resistant strain that harbors an alanine deletion at position 438 (Δ438A) in RpsA, a target of PZA associated with PZA resistance, but its role in causing PZA resistance has been inconclusive. Here, we introduced the RpsA Δ438A mutation along with the D123A mutation into the chromosome and demonstrated that these RspA mutations are indeed responsible for PZA resistance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535565 | PMC |
http://dx.doi.org/10.1128/AAC.02681-18 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!